'Digital health innovation is no longer an option, but a necessity for health systems'
BioSpectrum Asia|BioSpectrum Asia Sep 2021
The Asia Pacific Medical Technology Association (APACMed), has established a formal Digital Health Committee in order to focus on core advocacy themes such as interoperability, regulatory, cybersecurity, and reimbursement. On the latter point, the committee conducted global literature review combined with field research across the Asia Pacific, consulting public and private stakeholders, healthcare practitioners, and many other medical ecosystem players. APACMed study formulated the current state of Digital Health policies in the Asia Pacific, covering Australia and India as the two archetypes, which are poised uniquely with their own set of challenges and advantages. Roberta Sarno, Digital Health Manager, APACMed, Singapore trains the spotlight on the extensive research conducted by APACMed Digital Health Committee on these policy pathways for Asia Pacific. Edited excerpts;
Hithaishi C Bhaskar 
'Digital health innovation is no longer an option, but a necessity for health systems'

Roberta Sarno, Digital Health Manager, Asia Pacific Medical Technology Association (APACMed), Singaporedigital health technologies.

What are the key scenarios that may act as hurdles against a proactive digital health adoption in the APAC region?

Healthcare systems across the Asia Pacific (APAC) region are highly fragmented, and the level of Digital Health (DH) adoption and maturity varies from country to country. As such, there is a wide variation in how DH solutions are brought to each market. However, some common challenges impeding the scale up of DH in APAC include the lack of regulatory guidelines, harmonised interoperability standards, cybersecurity and reimbursement frameworks.

One of the key factors that could accelerate DH adoption and deliver healthcare to people in a more accessible, affordable, and scalable way is having in place robust reimbursement frameworks specific for DH. To this end, the APACMed Digital Health Committee has developed a position paper identifying these hurdles and proposing customised frameworks that countries in the region could adopt, depending on their level of readiness and regulatory standards.

The committee identified three key barriers to digital health adoption in APAC:

Lack of value assessment frameworks specific to digital health

Fragmented and non-fit-for-purpose funding and reimbursement efforts

Complex evidence generation requirements and health financing schemes that are not appropriate for digital health technologies.

Unlike traditional medical devices and drugs, for which hard clinical outcomes are primarily used as a measure of success, DH has the potential to also look at efficiency gains and other factors to measure value such as, reducing physical touch points and visits to the physician, relative value units, health outcomes, enhanced efficiency in cost, time and resources.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Sep 2021 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Sep 2021 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

BIOSPECTRUM ASIA DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024